Clarent (CLRN) Stock Price, News & Analysis

Company Overview

Clarent (OTCMKTS:CLRN) is a molecular diagnostics company focused on advancing precision oncology through tissue-based assay development and commercialization. The company leverages proprietary technologies in immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to deliver quantitative, reproducible data that help physicians and researchers tailor cancer treatment strategies to individual patients’ tumor profiles.

Clarent’s product portfolio includes a range of companion diagnostic tests designed to measure key biomarkers such as HER2, EGFR, PD-L1 and various gene rearrangements. These assays are offered under both laboratory-developed test (LDT) and kit formats and are validated to support patient selection for targeted therapies. In addition to standardized testing services, Clarent collaborates with pharmaceutical companies on co-development programs aimed at accelerating the regulatory approval of next-generation oncology drugs.

The company operates CLIA-certified laboratories in North America and maintains strategic partnerships throughout Europe and the Asia-Pacific region. Its service offerings extend from routine biomarker screening for community oncology centers to complex translational research support for academic institutions and global biopharma organizations. By combining advanced analytics with rigorous quality-management systems, Clarent aims to set a high standard for diagnostic accuracy and clinical utility.

Founded in 2003 and headquartered in California, Clarent’s leadership team comprises veterans from the molecular diagnostics and life sciences industries. Drawing on deep expertise in assay development, regulatory affairs and commercialization, the executive group is committed to expanding the reach of precision medicine and improving outcomes for patients with solid tumors worldwide.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0001
• Volume: 100 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLRN Stock Analysis - Frequently Asked Questions

How have CLRN shares performed this year?

Clarent's stock was trading at $0.0001 at the start of the year. Since then, CLRN shares have increased by 0.0% and is now trading at $0.0001.

How do I buy shares of Clarent?

Shares of CLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Computer and Technology
• Industry: Comm Network Software
• Sub-Industry: Computer Software
• Current Symbol: OTCMKTS:CLRN
• CIK: N/A
• Web: www.clarent.com
• Phone: (650) 306-7511
• Fax: 650-306-7512
• Employees: 850
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.08